As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Cue Biopharma, Inc. The largest reported stake is Mark E. Strome's, at 8.5%. 3 filings are on record since August 14, 2026 (Schedule 13G/A, October 8, 2026).
Sell to companies like Cue Biopharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Mark E. Strome · Sole voting: 1,674 · Shared voting: 643,242 · Sole dispositive: 1,674 · Shared dispositive: 643,242 · SCHEDULE 13G/A, 2026-10-08
- · Reporting person: Shao-Lee Lin · Sole voting: 467,166 · Shared voting: 0 · Sole dispositive: 467,166 · Shared dispositive: 0 · SCHEDULE 13D, 2026-08-21
- · Reporting person: Driehaus Capital Management LLC · Sole voting: 0 · Shared voting: 292,144 · Sole dispositive: 0 · Shared dispositive: 292,144 · SCHEDULE 13G, 2026-08-14
Cue Biopharma, Inc. has 3 Schedule 13D or 13G filings on record since 2026-08-14. 3 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 8.5% | 644,916 | SCHEDULE 13G/A, 2026-10-08 | 2026-07-14 | |
| Driehaus Capital Management LLC | 6.96% | 292,144 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| 6.2% | 467,166 | SCHEDULE 13D, 2026-08-21 | 2026-05-03 |
Holding shares or following this stake? See who's behind Cue Biopharma, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Cue Biopharma, Inc. and the records around it.
Cue Biopharma, Inc. elsewhere on the record
- Leadership changes Aug 2026
- Company profile and every filing Jul 2026
- Form D filing Jul 2026
- Form D filing May 2026
- Who owns it
Companies that share a holder
- Mark E. Strome also filed stake reports on 2 other companies: HeartBeam, Inc. (Aug 2026), Zivo Bioscience (Feb 2026)
- DRIEHAUS CAPITAL MANAGEMENT LLC also filed stake reports on 16 other companies: Cardinal Infrastructure Group Inc. (Aug 2026), Definium Therapeutics, Inc. (Aug 2026), Frequency Electronics, Inc. (Aug 2026)
Watch Cue Biopharma, Inc.
Get an email when Cue Biopharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cue Biopharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Cue Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cue Biopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Mark E. Strome | 1,674 | 643,242 | 1,674 | 643,242 | SCHEDULE 13G/A, 2026-10-08 |
| Strome Group, Inc. | 0 | 643,242 | 0 | 643,242 | SCHEDULE 13G/A, 2026-10-08 |
| Strome Investment Management, LP | 0 | 643,242 | 0 | 643,242 | SCHEDULE 13G/A, 2026-10-08 |
| Strome Dynasty, LLC | 0 | 50,000 | 0 | 50,000 | SCHEDULE 13G/A, 2026-10-08 |
| Strome Mezzanine Fund, LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-10-08 |
| Strome Mezzanine Fund II, LP | 0 | 593,242 | 0 | 593,242 | SCHEDULE 13G/A, 2026-10-08 |
| Driehaus Capital Management LLC | 0 | 292,144 | 0 | 292,144 | SCHEDULE 13G, 2026-08-14 |
| Shao-Lee Lin | 467,166 | 0 | 467,166 | 0 | SCHEDULE 13D, 2026-08-21 |
The latest filing identifies Cue Biopharma, Inc. by CUSIP 22978P205 and gives its principal executive office as 40 Guest Street, Boston, MA 02135 (SCHEDULE 13G/A, 2026-10-08).
What the percentages are based on
1. Mr. Strome: 8.50% 2. Strome Group, Inc.: 8.48% 3. Manager: 8.48% 4. Mezzanine: 0.00% 5. Mezzanine II: 7.82% 6.Mark E. Strome, SCHEDULE 13G/A, 2026-10-08
Source of funds (Item 3)
Employment Consideration On May 3, 2026, in connection with her appointment as CEO of the Issuer, the Reporting Person was granted a fully-vested restricted stock unit ("RSU") award for 327,537 shares of Common Stock (the "Lin RSU") and options to purchase Common Stock, of which 68,237 are exercisable within 60 days of this filing.Shao-Lee Lin, SCHEDULE 13D, 2026-08-21
Purpose of Transaction (Item 4)
Shao-Lee Lin
The Reporting Person intends to review her investment in the Common Stock and the Issuer's securities on a regular basis and, as a result thereof, may, directly or through one or more affiliates, at any time or from time to time determine, either alone or as part of a group, (i) to acquire additional securities of the Issuer, through open market purchases, privately negotiated transactions, or otherwise, (ii) to dispose of all or a portion of the securities of the Issuer beneficially owned by her in the open market, in privately negotiated transactions, or otherwise, or (iii) to take any other available course of action, which could involve one or more of the types of transactions or have one or more of the results specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). Any such acquisition or disposition or other transaction would be made in compliance with all applicable laws and regulations, and subject to the terms and conditions of any agreements between the Reporting Person and the Issuer. Notwithstanding anything contained herein, the Reporting Person intends to review her investment in the Issuer and the Issuer's performance and market conditions periodically and to take such actions with respect to her investment as she deems appropriate considering the circumstances existing from time to time. Accordingly, the Reporting Person specifically reserves the right to change her intention …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-21; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-08-14 | Driehaus Capital Management LLC | 6.96% | SCHEDULE 13G |
| 2026-08-21 | Shao-Lee Lin | 6.2% | SCHEDULE 13D |
| 2026-10-08 | Mark E. Strome | 8.5% | SCHEDULE 13G/A |
Questions about who owns Cue Biopharma, Inc.
Who owns Cue Biopharma, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Cue Biopharma, Inc.: Mark E. Strome (8.5%, Schedule 13G/A, filed 2026-10-08), Driehaus Capital Management LLC (6.96%, Schedule 13G, filed 2026-08-14) and Shao-Lee Lin (6.2%, Schedule 13D, filed 2026-08-21).
Who are the largest shareholders of Cue Biopharma, Inc.?
By the share each holder's latest filing reports, the largest holders of Cue Biopharma, Inc. on this page are Mark E. Strome (8.5%), Driehaus Capital Management LLC (6.96%) and Shao-Lee Lin (6.2%).
When did Mark E. Strome buy into Cue Biopharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Mark E. Strome on this page is the Schedule 13G/A, filed 2026-10-08, reporting 8.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Cue Biopharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 22, 2026 | Form D, private offering | $50M sold | Form D page | Source |
| June 2, 2026 | Leadership change: Sumita Ray appointed, Corporate Secretary, and 1 more | — | Leadership changes | Source |
| May 14, 2026 | Form D, private offering | $30M sold | Form D page | Source |
| May 1, 2026 | Leadership change: Lee Lin appointed, President and Chief Executive Officer | — | Leadership changes | Source |
Cue Biopharma, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Cue Biopharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.